Monitor for a prospectus supplement, which would signal an actual offering. The timing and type of security issued (equity vs. debt) will determine the impact. Given the company's recent debt issuance and history of losses, an equity offering could be dilutive, while a debt offering could increase leverage.
Price Chart
Executive Summary
Myriad Genetics filed an S-3 shelf registration to potentially raise up to $200 million through future offerings of common stock, preferred stock, depositary shares, debt securities, or warrants. This is a routine capital markets tool, not an immediate offering, and provides flexibility for opportunistic fundraising. The company recently secured a $125 million term loan, indicating it has near-term liquidity but may seek additional capital for strategic needs.
Key Financial Metrics
Key Facts
- Myriad Genetics filed an S-3 shelf registration to register up to $200 million of securities.
- The filing allows for future offerings of common stock, preferred stock, depositary shares, debt securities, or warrants, either individually or in units.
- The shelf registration is a procedural step and does not mean an immediate offering is taking place.
- The company recently entered into a $125 million secured term loan in July 2025, which was used to repay its previous credit facility.
- The company reported a net loss of $358 million for the nine months ended September 30, 2025, and has a history of negative cash flow from operations.
Financial Impact
Up to $200 million in potential future dilution or debt issuance.
Risk Factors
- Future equity offerings could dilute existing shareholders.
- Future debt offerings could increase the company's leverage and interest expense.
- The company's financial performance, including recent losses and impairment charges, may affect the terms and success of any future offering.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0000899923-26-000020 |
| Exhibit: exfilingfees.htm | 0000899923-26-000020 |
| Exhibit: ex231eyconsentfeb2026.htm | 0000899923-26-000020 |
| Document: myriad-2026sx322026.htm | 0000899923-26-000020 |
| Document: myriad-sx3x51opinionfebrua.htm | 0000899923-26-000020 |
| Document: 0000899923-26-000020-index-headers.html | 0000899923-26-000020 |
| Document: 0000899923-26-000020-index.html | 0000899923-26-000020 |
| Document: 0000899923-26-000020.txt | 0000899923-26-000020 |
| CONTEXT: 10-Q (2025-11-04) | 0000899923-25-000112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | 8-K | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Sep 16, 2026 16d ago | Press Release | $3.86 $4.01 | ▲ +3.89% | ▲ +1.32% | $4.54 (+17.62%) |
Aug 4, 2026 8w ago | Press Release | $3.17 $3.22 | ▼ −1.58% | ▼ −1.68% | $4.54 (−43.22%) |
Jul 30, 2026 9w ago | Press Release | $2.86 $3.26 | ▼ −13.99% | ▼ −10.47% | $4.54 (−58.74%) |
May 27, 2026 18w ago | Press Release | $3.93 $4.31 | ▲ +9.67% | ▲ +8.46% | $4.54 (+15.52%) |
Mar 17, 2026 28w ago | Press Release | $4.64 $4.68 | ▲ +0.86% | ▲ +1.58% | $4.54 (−2.16%) |
Feb 28, 2026 30w ago | Institutional Cluster | $5.01 $4.81 | ▼ −3.99% | ▼ −2.78% | $4.54 (−9.38%) |
Feb 24, 2026 31w ago | S-3 | $4.78 $5.28 | ▲ +10.46% | ▲ +11.56% | $4.54 (−5.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access